-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $31

Benzinga·11/11/2025 20:35:10
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $33 to $31.